Medivation Elects Wendy L. Yarno to Board of Directors

Medivation Elects Wendy L. Yarno to Board of Directors 
SAN FRANCISCO, CA -- (Marketwired) -- 04/29/13 --  Medivation, Inc.
(NASDAQ: MDVN) today announced that Wendy Yarno has been elected to
the Company's Board of Directors. Ms. Yarno has over 26 years of
experience in the pharmaceutical industry at Merck & Co. Inc.,
holding a number of executive positions in the marketing, sales and
human resources areas. Ms. Yarno most recently served as Chief
Marketing Officer at Merck, a position from which she retired in
"Wendy is an accomplished executive and her unique mix of experience
in both the commercialization of pharmaceutical products and human
resources management makes her an excellent addition to our board of
directors," said David Hung, M.D., president and chief executive
officer of Medivation, Inc. "We are pleased to welcome her to the
team and value the expertise she brings to Medivation." 
"Medivation is well positioned for future growth and I look forward
to working with the team to scale the organization and take full
advantage of the commercial opportunities that lie ahead and to help
Medivation continue its success and evolution with other potential
product candidates," said Ms. Yarno. 
In 2008, Ms. Yarno retired from Merck following a 26-year career at
the company in commercial and human resource positions of increasing
seniority, most recently Chief Marketing Officer. In that role, Ms.
Yarno led a global organization charged with all aspects of
supporting pre- and post-launch commercialization of pharmaceuticals
in more than 20 therapeutic areas. She also previously served as
General Manager, Cardiovascular/Metabolic U.S. Business Unit, where
she had P&L responsibility for Merck's largest therapeutic area, and
as Senior Vice President, Human Resources.  
Ms. Yarno currently serves on the Board of St. Jude Medical and also
serves on the Advisory Board and Board of Directors of multiple
privately held health care companies.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at 
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900 
Press spacebar to pause and continue. Press esc to stop.